SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from MERIDIAN BIOSCIENCE INC (CIK 0000794172) — Dec 18, 2020

MERIDIAN BIOSCIENCE INC (CIK 0000794172)
Date: Dec. 18, 2020 · CIK: 0000794172 · Accession: 0000892251-20-000035

AI Filing Summary & Sentiment

File numbers found in text: 333-250878

Date
December 18, 2020
Author
Not clearly detected
Form
CORRESP
Company
MERIDIAN BIOSCIENCE INC (CIK 0000794172)

Letter

Meridian Bioscience, Inc.

3471 River Hills Drive

Cincinnati, Ohio 45244

December 18, 2020

Via Edgar

1933 Act Filing Desk

Securities and Exchange Commission

450 Fifth Street, N.W.

Washington, D.C. 20549

Re: File No. 333-250878 Registration Statement on Form S-3

Filed November 23, 2020

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, the registrant named below hereby requests that the effective date of the Registration Statement on Form S-3, File No. 333-250878, be accelerated to, and that the Registration Statement be declared effective at, 10:00 a.m. (Washington D.C. time) on December 23, 2020 or as soon as practical thereafter. In this connection, the registrant confirms that it is aware of its obligations under the Securities Act of 1933 and the Securities Exchange Act of 1934 as such obligations relate to the proposed offering of securities.

In addition, the registrant acknowledges that:

•

should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

•

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

•

the registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very truly yours,
Meridian Bioscience, Inc.

Show Raw Text
CORRESP
1
filename1.htm

    Meridian Bioscience, Inc.

    3471 River Hills Drive

    Cincinnati, Ohio 45244

    December 18, 2020

    Via Edgar

    1933 Act Filing Desk

    Securities and Exchange Commission

    450 Fifth Street, N.W.

    Washington, D.C.  20549

              Re:
              File No. 333-250878
              Registration Statement on Form S-3

                Filed November 23, 2020

    Ladies and Gentlemen:

    Pursuant to Rule 461 of the Securities Act of 1933, the registrant named below hereby requests that the effective date
      of the Registration Statement on Form S-3, File No. 333-250878, be accelerated to, and that the Registration Statement be declared effective at, 10:00 a.m. (Washington D.C. time) on December 23, 2020 or as soon as practical thereafter.  In this
      connection, the registrant confirms that it is aware of its obligations under the Securities Act of 1933 and the Securities Exchange Act of 1934 as such obligations relate to the proposed offering of securities.

    In addition, the registrant acknowledges that:

              •

              should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it
                does not foreclose the Commission from taking any action with respect to the Registration Statement;

              •

              the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement
                effective, does not relieve the registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

              •

              the registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by
                the Commission or any person under the federal securities laws of the United States.

    Very truly yours,

    Meridian Bioscience, Inc.

    By:/s/ Bryan T. Baldasare

    Bryan T. Baldasare,

    Executive Vice President

    and Chief Financial Officer

    cc: Mr. Mark Reuter (Keating Muething & Klekamp PLL)